Wall Street Journal: How to Bring the Price of Health Care Into the Open

Shopping for health care based on price is still fairly rare and exceedingly difficult to do. However, the Wall Street Journal reports that the push toward price transparency is growing despite the barriers.

The Journal interviews American Hospital Association president, Rich Umbdenstock, who notes that hospitals "are absolutely in favor of price transparency," but their hands are tied because price transparency requires large-scale change and cooperation from both government and private payors. "If this were in our power to solve, we would have done it a long time ago," Umbdenstock is quoted as saying.

The report offers a concise overview of the argument for price transparency and efforts toward achieving this aim so far. However, it does not wade into all of the moral and ethical considerations that may arise from asking patients to take greater responsibility for their health care choices.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.